Hess KL, Hu X, Lansky A, Mermin J, Hall HI. Lifetime risk of a diagnosis of HIV infection in the United States. Annals Epidemiol 2017; 1; 27(4): 238-43.
Sheth AN, Rolle CP, Gandhi M. HIV pre-exposure prophylaxis for women. J Virus Erad 2016; 2(3): 149.
Siegler AJ, Mouhanna F, Giler RM, et al. Distribution of active PrEP prescriptions and the PrEP-to-need ratio, US, Q2 2017. Abstract presented at 25th Conference on Retroviruses and Opportunistic Infections (CROI 2018); Boston, MA 2018.
Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010; 363(27): 2587-99.
Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med 2012; 367(5): 399-410.
Thigpen MC, Kebaabetswe PM, Paxton LA, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med 2012; 367(5): 423-34.
Choopanya K, Martin M, Suntharasamai P, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, doubleblind, placebo-controlled phase 3 trial. Lancet 2013 15; 381(9883): 2083-90.
Baeten J, Heffron R, Kidoguchi L, et al. Near elimination of HIV transmission in a demonstration project of PrEP and ART. Abstract #24 presented at Conference on Retroviruses and Opportunistic Infections; 2015 February 23-26; Seattle, WA, USA.
Volk JE, Marcus JL, Phengrasamy T, et al. No new HIV infections with increasing use of HIV preexposure prophylaxis in a clinical practice setting. Clin Infec Dis 2015 1; 61(10): 1601-3.
Liu AY, Cohen SE, Vittinghoff E, et al. Preexposure prophylaxis for HIV infection integrated with municipal-and community-based sexual health services. JAMA Intern Med 2016; 1 76(1): 75-84.
Delaney KP, Sanchez T, Bowles K, Oraka E, DiNenno E, Sullivan P. Awareness and use of PrEP appear to be increasing among internet samples of US MSM. Abstract #889 presented at: Conference on Retroviruses and Opportunistic Infections; 2016 February 22- 25; Boston, MA, USA.
Young I, McDaid L. How acceptable are antiretrovirals for the prevention of sexually transmitted HIV?: A review of research on the acceptability of oral pre-exposure prophylaxis and treatment as prevention. AIDS Behav 2014; 18(2): 195-216.
Edelstein Z, Mensah N, Scanlin K, Cutler B, Myers J. Awareness of HIV prevention innovations among women of color in NYC: HIV self-tests and pre-exposure prophylaxis (PrEP). Presented at 142nd APHA Annual Meeting and Exposition; 15-19 November 2014; New Orleans, LA, USA.
Doblecki-Lewis S, Lester L, Schwartz B, Collins C, Johnson R, Kobetz E. HIV risk and awareness and interest in pre-exposure and post-exposure prophylaxis among sheltered women in Miami. Int J STD AIDS 2016; 27(10): 873-81.
Walters SM, Reilly KH, Neaigus A, Braunstein S. Awareness of pre-exposure prophylaxis (PrEP) among women who inject drugs in NYC: the importance of networks and syringe exchange programs for HIV prevention. Harm Reduct J 2017; 14(1): 40.
Collier KL, Colarossi LG, Sanders K. Raising awareness of pre-exposure prophylaxis (PrEP) among women in New York City: community and provider perspectives. J Health Commun 2017; 22(3): 183-9.
Auerbach JD, Kinsky S, Brown G, Charles V. Knowledge, attitudes and likelihood of pre-exposure prophylaxis (PrEP) use among US women at risk of acquiring HIV. AIDS Patient Care and STDs 2015; 29(2): 102-10.
Smith DK, Van Handel M, Wolitski RJ, et al. Vital signs: estimated percentages and numbers of adults with indications for preexposure prophylaxis to prevent HIV acquisition—United States, 2015. MMWR Morb Mortal Wkly Rep 2015; 64(46): 1291-5.
Mera R, McCallister S, Palmer B, Mayer G, Magnuson D, Rawlings K. Truvada for HIV pre-exposure prophylaxis (PrEP) utilization in the United States: 2013-2015. Abstract TUAX0105LB presented at the 21st International AIDS Conference; 2016 July 18-22; Durban, South Africa.
Bush S, Magnuson D, Rawlings M, Hawkins T, McCallister S, Mera Giler R. Racial characteristics of ftc/tdf for pre-exposure prophylaxis users in the us. Abstract 2651 presented at the American Society for Microbiology (ASM Microbe) 2016; 2016 June 16-20, 2016. Boston, MA, USA.
Adimora A, et al. New approaches for HIV prevention trials. Clin Infect Dis 2017; 65: 324.
Beymer MR, Weiss RE, Sugar CA, et al. Are centers for disease control and prevention guidelines for preexposure prophylaxis specific enough? formulation of a personalized hiv risk score for pre-exposure prophylaxis initiation. Sex Trans Dis 2017; 44(1): 48-56.
Aaron E, Blum C, Seidman D, et al. Delivery of HIV preexposure prophylaxis for women in the United States. AIDS Patient Care STDs 2018; 32(1): 16-23.
Willie TC, Stockman JK, Overstreet NM, Kershaw TS. Examining the impact of intimate partner violence type and timing on pre-exposure prophylaxis awareness, interest, and coercion. AIDS Behav 2018; 22(4): 1190-200.
DiClemente RJ, Wingood GM, Sales JM, et al. Efficacy of a telephone-delivered sexually transmitted infection/human immunodeficiency virus prevention maintenance intervention for adolescents: a randomized clinical trial. JAMA Pediatr 2014; 168(10): 938-46.
Curran TM, Monahan JL, Samp JA, Coles VB, DiClemente RJ, Sales J. Sexual risk among African American women: Psychological factors and the mediating role of social skills. Commun Q 2016; 64(5): 536-52.
Collier KL, Colarossi LG, Sanders K. A PrEP information and self-screening tool for women. AIDS Educ Prev 2018; 30(1): 13-25.
Patel A, Goparaju L, Sales JM, et al. Predictors of PrEP eligibility among at−risk women in the Southern United States. Poster presented at: Annual CROI meeting; 2018 March; Boston, MA, USA.
Corneli A, Perry B, Agot K, Ahmed K, Malamatsho F, Van Damme L. Facilitators of adherence to the study pill in the FEM-PrEP clinical trial. PLoS One 2015; 10(4): e0125458.
van der Straten A, Stadler J, Luecke E, et al. Perspectives on use of oral and vaginal antiretrovirals for HIV prevention: the VOICE‐C qualitative study in Johannesburg, South Africa. J Int AIDS Soc 2014; 17: 19146.
Seidman D, Carlson K, Weber S, Witt J, Kelly PJ. United States family planning providers’ knowledge of and attitudes towards preexposure prophylaxis for HIV prevention: a national survey. Contraception 2016; 93(5): 463-9.
Frost JJ, Gold RB, Bucek A. Specialized family planning clinics in the United States: why women choose them and their role in meeting women’s health care needs. Womens Health Issues 2012; 22(6): e519-25.
Seidman D, Weber S. Integrating preexposure prophylaxis for human immunodeficiency virus prevention into women’s health care in the United States. Obstet Gynecol 2016; 128(1): 37-43.
Gavin L, Pazol K. Update: providing quality family planning services - recommendations from cdc and the u.s. office of population affairs. MMWR Morb Mortal Wkly Rep 2016; 65(9): 231-4.
Mugo NR, Ngure K, Kiragu M, Irungu E, Kilonzo N. PrEP for Africa: What we have learnt and what is needed to move to program implementation. Curr Opin HIV AIDS 2016; 11(1): 80.